Longhorn Vaccines v. Spectrum Solutions — Federal Circuit Appeal Voluntarily Dismissed
Longhorn Vaccines & Diagnostics and Spectrum Solutions filed a joint stipulation of voluntary dismissal at the Federal Circuit after 733 days of appellate proceedings over US9212399B2, a patent covering biological specimen collection and transport systems. Each party bears its own costs, leaving the merits of the patentability dispute unresolved on the public record.
A two-year Federal Circuit patentability fight ends without a merits ruling
Longhorn Vaccines & Diagnostics, LLC initiated appellate proceedings at the United States Court of Appeals for the Federal Circuit on 6 July 2023, appealing a patentability determination involving US9212399B2. The patent covers a biological specimen collection and transport system and associated methods of use — a technology with direct relevance to diagnostic and public-health supply chains. The defendant-appellee, Spectrum Solutions, LLC, was represented by Knobbe Martens, while Longhorn retained Fried, Frank, Harris, Shriver & Jacobson LLP.
The case concluded on 8 July 2025 when the Federal Circuit issued an order giving effect to the parties’ joint stipulation of voluntary dismissal. The appeals were dismissed in their entirety, with each party directed to bear its own costs. Because the dismissal was voluntary and agreed upon by both sides, the court issued no ruling on the underlying patentability or invalidity questions — the substantive dispute between the parties remains formally unresolved in the appellate record.
The 733-day duration before dismissal suggests protracted parallel negotiations or strategic reassessment, though the public record does not disclose whether a settlement was reached, a licensing arrangement was struck, or the parties simply elected to withdraw. The mutual cost-bearing term is consistent with a negotiated resolution, though this cannot be confirmed from the available record. The absence of a merits decision means the validity of US9212399B2 was never adjudicated at the Federal Circuit level.
Filing to Voluntary dismissal in 733 days
733 days — above the median Federal Circuit appeal resolution window
Voluntarily dismissed: what the joint stipulation means for both parties
Voluntary dismissal at the Federal Circuit: no merits ruling
A joint stipulation of voluntary dismissal terminates appellate proceedings without the court adjudicating the substance of the dispute. The Federal Circuit’s order here is purely procedural — it gives effect to the parties’ agreement to withdraw. No ruling was made on patentability, invalidity, or claim scope. As a result, neither party gains a precedential legal finding from these proceedings.
Procedural exit — no merits decidedWith or without prejudice? The public record is silent
The order records a voluntary dismissal but does not specify whether it was entered with or without prejudice. This distinction matters: a dismissal with prejudice bars refiling; without prejudice leaves future action open. The joint stipulation and the court’s order do not resolve this question on the face of the public record. Practitioners should treat the position of US9212399B2’s validity as legally undetermined unless further filings clarify the terms.
Prejudice status: unconfirmedLonghorn’s patent survives without a validity ruling — for now
Because the Federal Circuit did not issue a merits decision, US9212399B2 has not been invalidated through this proceeding. Longhorn Vaccines retains the patent in its current form. However, the patent also did not receive the benefit of a Federal Circuit affirmance that would strengthen its enforceability. Any future assertion of this patent will proceed without appellate precedent supporting its validity.
Patent survives; validity untestedSpectrum avoids an adverse ruling but gains no cancellation
Spectrum Solutions exits these proceedings without having secured a court-ordered cancellation or invalidity finding against US9212399B2. If the underlying patentability challenge succeeded at a lower tribunal, that outcome’s status now depends on what — if anything — the parties agreed to outside of court. The absence of a Federal Circuit ruling means Spectrum cannot cite this case as precedent should the patent be asserted against it again.
No cancellation confirmed on recordFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Longhorn Vaccines & Diagnostics, LLC | Company | Diagnostics and vaccines IP licensor — holder of US9212399B2Search in Eureka ↗ |
| Defendant | Spectrum Solutions, LLC | Company | Spectrum Solutions, LLC — biological specimen collection product companySearch in Eureka ↗ |
| Plaintiff counsel | Nicole M. Jantzi | Attorney | Counsel for Longhorn Vaccines & Diagnostics, LLCSearch in Eureka ↗ |
| Plaintiff law firm | Fried, Frank, Harris, Shriver & Jacobson LLP | Law Firm | Representing Longhorn Vaccines & Diagnostics, LLCSearch in Eureka ↗ |
| Defendant counsel | Joseph F. Jennings | Attorney | Counsel for Spectrum Solutions, LLCSearch in Eureka ↗ |
| Defendant law firm | Knobbe Martens Olson & Bear, LLP | Law Firm | Representing Spectrum Solutions, LLCSearch in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | Court of Appeals for the Federal CircuitSearch in Eureka ↗ |
Official order — verbatim text
The Federal Circuit’s order is narrowly procedural: it gives effect to a joint stipulation and dismisses the appeals without reaching any substantive question of patentability or claim validity. The cost-neutrality clause — each party bears its own costs — is notable in that it avoids any inference of a prevailing party, which is consistent with a negotiated exit. No legal standard of review was applied, and no findings were made on the merits of the invalidity or cancellation grounds that formed the basis of the original appeal.
US9212399B2 — biological specimen collection and transport system
US9212399B2, assigned application number US14/149278, protects a biological specimen collection and transport system and associated methods of use. Patents in this category typically cover engineered containers, stabilising media, or integrated collection devices designed to preserve biological material — such as saliva, blood, or swabs — during transit from collection point to laboratory. The technical domain intersects materials science, microbiology, and device engineering, and has seen heightened commercial relevance following expanded demand for at-home and point-of-care diagnostics.
For Longhorn Vaccines & Diagnostics, this patent likely represents a key asset in a licensing or enforcement strategy targeting manufacturers and distributors of specimen collection kits. Competitors and OEM suppliers in the diagnostics supply chain — particularly those commercialising transport media or integrated collection-and-stabilisation systems — face potential infringement exposure if their products overlap with the claimed inventions. The fact that Spectrum Solutions, a company active in this exact product category, pursued a patentability challenge through to the Federal Circuit level suggests the claims were viewed as commercially significant and potentially broad.
Should you run an FTO against US9212399B2?
Any R&D team or product group commercialising biological specimen collection devices, transport media, swab-based collection kits, or stabilisation systems should assess their exposure to US9212399B2. The patent’s claims — covering both the system and its method of use — can create dual infringement vectors: making or selling the device, and using it in a collection workflow. Because this patent’s validity was never adjudicated at the Federal Circuit, it carries enforcement risk that a lapsed or invalidated patent would not.
PatSnap Eureka’s FTO Search Agent can rapidly map the claim landscape of US9212399B2 against your product specifications, identify file history disclaimers that may narrow scope, and surface any continuation or divisional family members that could extend coverage. With the underlying patentability dispute unresolved, a structured FTO review is the most reliable way to quantify your exposure before product launch or scale-up in the specimen collection and transport segment.
Run a freedom-to-operate analysis on US9212399B2 to assess your product’s exposure
Run FTO in Eureka →Similar Federal Circuit patentability appeals in biological diagnostics
Federal Circuit appeals involving patentability challenges to biological specimen collection and diagnostic technology patents, including voluntary dismissals and PTAB-origin invalidity actions.
What this case signals for the biological specimen collection IP landscape
A voluntarily dismissed Federal Circuit patentability appeal leaves US9212399B2 in legal limbo — with consequences for diagnostics IP strategy.
Unresolved patentability creates ongoing uncertainty for product teams
When a Federal Circuit patentability appeal is voluntarily dismissed without a merits ruling, the challenged patent’s validity status is neither confirmed nor denied. Companies operating in the biological specimen collection and transport space should treat US9212399B2 as a live enforcement risk until its scope is formally adjudicated or the patent expires.
Joint cost-bearing terms are consistent with negotiated resolution
The stipulation that each party bears its own costs is a common feature of cases that settle quietly before a court issues judgment. While the public record does not confirm a settlement, this cost structure — combined with the 733-day timeline — suggests the parties likely reached a commercial arrangement. Monitoring assignee activity on US9212399B2 is advisable.
Longhorn v Spectrum — key questions answered
The Federal Circuit appeal in case 23-2114 was voluntarily dismissed by joint stipulation of both parties on 8 July 2025, after 733 days of proceedings. No merits ruling was issued on the patentability of US9212399B2. Each party was ordered to bear its own costs.
No. The Federal Circuit did not issue a substantive ruling on the validity or patentability of US9212399B2. The appeal was voluntarily dismissed before any merits determination was made. The patent’s validity status remains undecided at the appellate level based on the public record of this case.
A voluntary dismissal at the Federal Circuit, effected by joint stipulation, terminates the appeal without the court adjudicating the underlying legal questions. It is a procedural exit that leaves the substantive dispute — here, the patentability of US9212399B2 — formally unresolved. It does not constitute a finding for or against either party on the merits.
US9212399B2 covers a biological specimen collection and transport system and associated methods of use. This class of patent typically protects integrated devices or media used to collect, stabilise, and transport biological samples — such as swabs, saliva, or blood — from the point of collection to a laboratory for analysis.
The public record of case 23-2114 does not resolve this question. Estoppel implications depend on the grounds raised in the original PTAB proceeding, whether a final written decision was issued before the appeal, and the specific terms of the dismissal stipulation. Practitioners should conduct a full file history review before filing any new post-grant challenge.
PatSnap Eureka searches patents and litigation data to answer instantly.